Education
About Us
Working with TipRanks
Follow Us
Eyenovia Inc (EYEN)
NASDAQ:EYEN
EYEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.23 - $124.80
Previous CloseN/A
Volume25.52M
Average Volume (3M)412.94K
Market Cap
$2.65M
Enterprise Value$41.79M
Total Cash (Recent Filing)$19.73M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.42
Next Earnings
May 14, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-58.50
Shares Outstanding2,100,000
10 Day Avg. Volume945,487
30 Day Avg. Volume412,940
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)91.04
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market Cap15.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.22
Forecast
1Y Price Target
$2.00Price Target Upside58.73% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
FDA ApprovalsEyenovia retains two FDA approvals for its Optejet delivery system, enhancing its credibility and potential market presence.
Market ExpansionEyenovia's efforts to pursue an additional 200 active practices build on the current 230 offices for Mydcombi adoption, signaling potential expansion and increased market penetration.
Mergers And PartnershipsThe proposed merger of topical ophthalmic platforms could present the next constructive chapter for Optejet and broader development.
Bears Say
Analyst RatingThe rating for Eyenovia has been changed to Neutral from Buy, reflecting a more cautious outlook.
Clinical Trial ChallengesThe Phase 3 CHAPERONE study did not meet its primary endpoint for pediatric myopia, leading to the discontinuation of the MicroPine study.
Investment RisksRisks to the investment thesis include failure of products and/or candidates to achieve peak commercial revenue estimates due to market size, penetration rates, and/or pricing.
---
Ownership Overview
11.34% Insiders
2.29% Mutual Funds
9.00% Other Institutional Investors
75.71% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EYEN FAQ
What was Eyenovia Inc’s price range in the past 12 months?
Eyenovia Inc lowest stock price was $1.23 and its highest was $124.80 in the past 12 months.
What is Eyenovia Inc’s market cap?
Eyenovia Inc’s market cap is $2.65M.
When is Eyenovia Inc’s upcoming earnings report date?
Eyenovia Inc’s upcoming earnings report date is May 14, 2025 which is in 46 days.
How were Eyenovia Inc’s earnings last quarter?
Currently, no data Available
Is Eyenovia Inc overvalued?
According to Wall Street analysts Eyenovia Inc’s price is currently Undervalued.
Does Eyenovia Inc pay dividends?
Eyenovia Inc does not currently pay dividends.
What is Eyenovia Inc’s EPS estimate?
Eyenovia Inc’s EPS estimate is -0.1.
How many shares outstanding does Eyenovia Inc have?
Eyenovia Inc has 2,100,000 shares outstanding.
What happened to Eyenovia Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Eyenovia Inc?
Currently, no hedge funds are holding shares in EYEN
---
Company Description
Eyenovia Inc
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.
---
EYEN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook with significant advances in product development and strategic partnerships but was overshadowed by financial challenges and a need for further capital. The company is making strong progress in product launches and regulatory approvals but faces ongoing financial hurdles that need addressing.Read More>---
EYEN Stock 12 Month Forecast
Average Price Target
$2.00
▲(58.73% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Aldeyra Therapeutics
―
Ocular Therapeutix
―
Ocugen
―
Kala Pharmaceuticals
―
---